790 results on '"Yau, T."'
Search Results
2. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
3. 53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma
4. A case of severe pulmonary blastomyces in an immunocompetent 39-year old male
5. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
6. HEART FAILURE IMPAIRS BONE MARROW HEMATOPOIETIC STEM CELL FUNCTION AND RESPONSES TO INJURY
7. Replication study of SNP associations for colorectal cancer in Hong Kong Chinese
8. Can’t see, can’t climb a tree, can’t defecate pain free: reactive arthritis due to chlamydial proctitis
9. Improving adherence to and effectiveness of a vancomycin continuous infusion protocol, a pilot quality improvement project
10. Research capability and aspirations of antimicrobial pharmacists: survey of UKCPA pin membership
11. 83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
12. 67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
13. 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
14. 713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240
15. STOP— a training intervention to optimise treatment for smoking cessation in community pharmacies: cluster randomised controlled trial
16. SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
17. SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study
18. A Real Circuit Breaker: Hyperhemolysis Syndrome Related to the VA-ECMO Circuit?
19. COVID-19-associated pulmonary aspergillosis (CAPA): review of utility of local CAPA guideline and MDT in directing diagnosis and antifungal stewardship
20. Molecular profiling of bacterial blight resistance in Malaysian rice cultivars
21. VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
22. Corrosion of Zirconium and its Alloys
23. 84 - A case of severe pulmonary blastomyces in an immunocompetent 39-year old male
24. 138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
25. OPENING THE CARMS BLACK BOX: THE IMPORTANCE OF VARIOUS ASPECTS OF THE CARMS APPLICATION FOR CARDIAC SURGERY APPLICANTS
26. What determines treatment success and future perspectives?
27. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
28. 981P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
29. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study
30. HEART FAILURE IMPAIRS BONE MARROW HEMATOPOIETIC STEM CELL FUNCTION AND RESPONSES TO INJURY
31. LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial
32. 100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)
33. O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study
34. Abstract No. 117 A phase 3, double-blind, randomized study of nivolumab and Ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma
35. Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
36. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer
37. The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells
38. Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles
39. The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study
40. Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity
41. 46O Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
42. DOES GORETEX IMPROVE OUTCOMES IN LVAD EXPLANTATION-HEART TRANSPLANTATION?
43. 319 - Can’t see, can’t climb a tree, can’t defecate pain free: reactive arthritis due to chlamydial proctitis
44. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass
45. Corrosion of Zirconium and its Alloys
46. Validation of the Chinese version of the Short-form Supportive Care Needs Survey Questionnaire (SCNS-SF34-C)
47. 1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
48. 1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240
49. O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
50. O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.